Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
995 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
| NCT03006926 | A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 104 | Eisai Co., Ltd.INDUSTRY | 7 | Dec 13, 2023 | clinicaltrials |
| NCT03383692 |
| Study of DS-8201a for Participants With Advanced Solid Malignant Tumors |
| completed |
| Phase 1 |
| 40 |
| Daiichi Sankyo Co., Ltd.INDUSTRY |
| 3 |
| Dec 11, 2023 |
| clinicaltrials |
| NCT02608268 | Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 252 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 6, 2023 | clinicaltrials |
| NCT03900377 | Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma | completed | Phase 1 / Phase 2 | 37 | SymBio PharmaceuticalsINDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02733042 | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia(FUSION NHL 001) | completed | Phase 1 / Phase 2 | 106 | CelgeneINDUSTRY | 7 | Nov 18, 2023 | clinicaltrials |
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors(CheckMate358) | completed | Phase 1 / Phase 2 | 578 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT04299880 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | completed | Phase 1 | 7 | Sumitomo Pharma America, Inc.INDUSTRY | 4 | Nov 8, 2023 | clinicaltrials |
| NCT03671564 | Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 1 | 14 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02782468 | A Study of Pevonedistat in Adult East Asian Participants | completed | Phase 1 | 23 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 3, 2023 | clinicaltrials |
| NCT03099109 | A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors | completed | Phase 1 | 209 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 17, 2023 | clinicaltrials |
| NCT03188965 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 229 | BayerINDUSTRY | 7 | Oct 11, 2023 | clinicaltrials |
| NCT03730337 | Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors | completed | Phase 1 | 24 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04546074 | Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma | unknown | Phase 1 / Phase 2 | 22 | Keio UniversityOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04145700 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | terminated | Phase 1 / Phase 2 | 23 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 13, 2023 | clinicaltrials |
| NCT04293094 | Study of AMG 650 in Adult Participants With Advanced Solid Tumors | completed | Phase 1 | 66 | Volastra Therapeutics, Inc.INDUSTRY | 7 | Aug 24, 2023 | clinicaltrials |
| NCT03314922 | A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | completed | Phase 1 | 17 | Incyte CorporationINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03064763 | Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma | completed | Phase 1 | 18 | AmgenINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05074550 | Safety Evaluation Study for Patients With Polycythemia Vera | unknown | Phase 1 | 6 | Perseus Proteomics Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT02584634 | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | terminated | Phase 1 / Phase 2 | 43 | PfizerINDUSTRY | 5 | Jul 7, 2023 | clinicaltrials |
| NCT01268293 | A Study of E7080 in Subjects With Solid Tumor | completed | Phase 1 | 9 | Eisai Co., Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913115 | A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer | completed | Phase 1 | 6 | AmgenINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03499444 | A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor | completed | Phase 1 | 29 | pharmaand GmbHINDUSTRY | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05883007 | Dose Optimized BNCT for Head and Neck Cancer(ST-BNCT2001) | unknown | Phase 1 | 30 | Southern Tohoku BNCT Research CenterOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04495127 | Selumetinib Paediatric NF1 Japan Study | completed | Phase 1 | 12 | AstraZenecaINDUSTRY | 1 | Apr 26, 2023 | clinicaltrials |
| NCT03242889 | A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | terminated | Phase 1 | 24 | AmgenINDUSTRY | 6 | Apr 12, 2023 | clinicaltrials |
| NCT04557384 | A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer | terminated | Phase 1 | 3 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 27, 2023 | clinicaltrials |
| NCT00585195 | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer(PROFILE 1001) | completed | Phase 1 | 596 | PfizerINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT03238651 | A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) | terminated | Phase 1 | 17 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT03370302 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies | terminated | Phase 1 | 28 | Calithera Biosciences, IncINDUSTRY | 3 | Feb 8, 2023 | clinicaltrials |
| NCT03599518 | DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04835714 | A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 1 | Feb 1, 2023 | clinicaltrials |
| NCT02342665 | Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL | completed | Phase 1 / Phase 2 | 25 | BayerINDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03430479 | Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Kyoto Breast Cancer Research NetworkOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT01625286 | Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients(BEECH) | completed | Phase 1 / Phase 2 | 148 | AstraZenecaINDUSTRY | 11 | Jan 18, 2023 | clinicaltrials |
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | terminated | Phase 1 | 142 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 21, 2022 | clinicaltrials |
| NCT02412306 | Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 66 | AmgenINDUSTRY | 1 | Dec 12, 2022 | clinicaltrials |
| NCT03082209 | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | completed | Phase 1 | 153 | AbbVieINDUSTRY | 4 | Dec 9, 2022 | clinicaltrials |
| NCT03386942 | A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors | completed | Phase 1 | 82 | Eisai Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT02857270 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | completed | Phase 1 | 210 | Eli Lilly and CompanyINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT03009344 | A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 7 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03172819 | Special Combination of OBP-301 and Pembrolizumab | completed | Phase 1 | 22 | Toshihiko DoiOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02734615 | Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | terminated | Phase 1 | 199 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 1, 2022 | clinicaltrials |
| NCT04270591 | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 183 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT04462952 | Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Jul 25, 2022 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials